Acute Myelocytic Leukemia

Acute myelocytic leukemia (also called acute myeloid leukemia) is a fast-growing blood and bone marrow cancer. It starts when very early myeloid cells in the marrow (myeloblasts) gain DNA changes. These changes make the cells grow out of control and not mature. The abnormal blasts crowd out healthy red cells, white cells, and platelets. Because of this, people develop anemia, infections, and bleeding. AML can also form solid masses called myeloid sarcomas (chloromas) or spread to the brain, skin, gums, or other organs. Diagnosis is made with blood tests and bone marrow tests plus genetic testing. Doctors also look for the exact gene changes because they help name the AML type and guide care. Cancer.gov+1

Acute myelocytic leukemia (also called acute myeloid leukemia or acute non-lymphocytic leukemia) is a fast-growing cancer of the bone marrow. It starts from immature myeloid cells that should become healthy white cells, red cells, or platelets. In AML, these blasts grow out of control and crowd out normal cells. People may develop anemia, infections, or bleeding. Diagnosis is made by blood tests, bone-marrow biopsy, and genetic tests. Treatment often starts quickly and may include chemotherapy, targeted pills, antibodies, and sometimes stem cell transplant. Cure is possible, especially when treatment is started early and is matched to the leukemia’s genetic changes.

Other names

AML is also called acute myelocytic leukemia, acute myelogenous leukemia, acute myeloblastic leukemia, and acute non-lymphocytic leukemia (ANLL). Older terms include acute granulocytic leukemia and acute myelomonocytic leukemia for certain subtypes. Today, many cases are named by their genetic changes, such as AML with NPM1 mutation, t(8;21) RUNX1::RUNX1T1, inv(16)/t(16;16) CBFB::MYH11, or t(15;17) PML::RARA (now usually called acute promyelocytic leukemia/APL). College of American PathologistsASH Publications

Types

Doctors now classify AML mainly by the gene changes in the leukemia cells. Two widely used systems (WHO 2022 and the International Consensus Classification, ICC 2022) are very similar and focus on “AML with defining genetic abnormalities,” “AML myelodysplasia-related,” therapy-related AML, and AML not otherwise specified (NOS). Some AML types are defined even when blasts are below 20% if a key abnormality is present. College of American PathologistsPMC+1

Common categories you may see in reports

• AML with recurrent genetic abnormalities. Examples include:
  t(8;21) RUNX1::RUNX1T1; inv(16)/t(16;16) CBFB::MYH11; t(15;17) PML::RARA (APL); mutated NPM1; biallelic CEBPA; AML with BCR::ABL1 (rare); KMT2A-rearranged; DEK::NUP214; NUP98-rearranged, etc. These labels tell doctors about likely behavior and treatment needs. ASH PublicationsNature

• AML myelodysplasia-related (AML-MR). AML that arises from prior myelodysplastic syndrome (MDS), myelodysplasia-related gene mutations, or MDS-type chromosome changes. PMC

• Therapy-related AML (t-AML). AML that develops after prior chemotherapy and/or radiation for another condition. Cancer.gov

• AML, NOS. When no defining abnormality is found, doctors may describe the cells (e.g., myeloblastic, myelomonocytic, monocytic) by their appearance and markers. ASH Publications

• Myeloid sarcoma (chloroma). A mass of AML cells outside the marrow; it can occur alone or with marrow disease. Cancer.gov

Note on blast thresholds: ICC often allows diagnosis at ≥10% blasts for many genetic-defined AML types; WHO 2022 is similar but differs on some details. AML with BCR::ABL1 and with CEBPA still require ≥20% blasts in WHO 2022. Your pathology report notes which system was used. PMC+1

Causes and risk factors

“Cause” in AML usually means risk factor—something that makes AML more likely. Most cases result from acquired DNA changes that build up over time. Cancer.gov

1. Older age. Risk rises with age because marrow cells collect more DNA damage over the years. Cancer.gov

2. Male sex. Men have a slightly higher risk for reasons that are not fully understood. Cancer.gov

3. Cigarette smoking. Smoke contains benzene and other chemicals that harm marrow DNA. Cancer.gov+1

4. Benzene exposure. Long-term workplace or environmental benzene exposure increases AML risk. Cancer.govCancer Research UKPMC

5. High-dose radiation. Nuclear accidents or atomic bomb exposure increased leukemia risk; prior therapeutic radiation also adds risk. American Cancer Society

6. Prior chemotherapy. Alkylating agents and topoisomerase II inhibitors can damage marrow DNA and lead to therapy-related AML. Cancer.gov

7. Previous myelodysplastic syndrome (MDS). MDS can transform into AML. Cancer.gov

8. Previous myeloproliferative neoplasm (e.g., PV, ET, MF). These can evolve to AML, especially after many years or certain treatments. ASH Publications

9. Family-linked AML syndromes. Rare inherited mutations (RUNX1, CEBPA, GATA2, DDX41 and others) raise risk. ASH Publications

10. Down syndrome and other congenital conditions. Trisomy 21 and syndromes like Fanconi anemia, Bloom, Li-Fraumeni, and Shwachman-Diamond increase risk. Cancer.gov

11. Clonal hematopoiesis (CHIP). Some older adults have small clones with mutations (e.g., DNMT3A, TET2). A tiny portion progress to AML over time. ASH Publications

12. Obesity. Several studies link higher body weight to higher AML risk, possibly via inflammation and marrow stress. PMC

13. Chronic solvent exposures (besides benzene). Some petroleum and rubber-industry solvents are associated with myeloid cancers. PMC

14. Pesticide exposures. Certain occupational pesticide exposures are associated with myeloid leukemias in population studies. (Association, not proof.) PMC

15. Prior radiation plus chemotherapy. Combined treatments further increase t-AML risk compared with either alone. Cancer.gov

16. Chronic inflammation and autoimmune disease. These conditions can stress marrow and sometimes precede AML/MDS. (Risk is small but real.) Cancer Research UK

17. Hematologic disorders with cytopenias. Long-standing, unexplained low blood counts may reflect clonal marrow disease that can progress to AML. ASH Publications

18. Secondhand smoke. It contains benzene; repeated exposure adds risk over time. Cancer.gov

19. Environmental disasters. Large radiation or chemical events can raise community leukemia rates. American Cancer Society

20. Mostly, random DNA errors. In many people no clear exposure is found; the disease results from chance DNA damage in marrow cells. Cancer.gov

Common symptoms

1. Tiredness and weakness. Fewer red cells carry less oxygen, so daily tasks feel hard. Cancer.gov

2. Shortness of breath. Even light activity can cause breathlessness due to anemia. Rogel Cancer Center

3. Pale skin. Low red cells make the skin look pale or gray. Cancer.gov

4. Fever. Fever can come from infection or from the leukemia itself. Cancer.gov

5. Frequent infections. Abnormal white cells do not fight germs well. Cancer.gov

6. Easy bruising. Low platelets cause bruises after minor bumps. Rogel Cancer Center

7. Bleeding gums or nosebleeds. Platelet shortage leads to gum and nose bleeding. Rogel Cancer Center

8. Petechiae. Tiny red or purple spots on the skin are small bleeds. Rogel Cancer Center

9. Bone or joint pain. The marrow is overfull of blasts, which can hurt. Cancer.gov

10. Swollen gums. Certain AML types infiltrate the gums and make them thick. Cancer.gov

11. Enlarged spleen or liver. Fullness or discomfort under the ribs can occur when these organs enlarge. Cancer.gov

12. Weight loss or poor appetite. Cancer and infections reduce appetite and weight. Rogel Cancer Center

13. Night sweats. Heavy sweating at night can reflect infection or high tumor activity. Cancer.gov

14. Headache or confusion. Very high white counts or CNS spread can reduce blood flow or seed the brain. Cancer.gov

15. Skin lumps or rashes. Leukemia cutis or myeloid sarcomas form firm skin nodules or plaques. Cancer.gov

Diagnostic tests

A) Physical examination (what the clinician checks)

1. General appearance and vital signs. Doctors look for fever, fast heart rate, fast breathing, and low blood pressure that suggest infection or anemia stress. Cancer.gov

2. Skin and mucosa check. They look for pallor, petechiae, bruises, or gum swelling that point to low counts or leukemic infiltration. Rogel Cancer Center

3. Lymph nodes and organs. The doctor feels the neck, armpits, and groin for nodes and checks the liver and spleen for enlargement, which can occur in AML. Cancer.gov

4. Neurologic screening. Headache, weakness, or confusion may suggest very high white counts or CNS involvement and guide further testing. Cancer.gov

B) “Manual” procedural tests (hands-on procedures and slide-based tests)

5. Peripheral blood smear. A drop of blood is smeared on a glass slide and examined by hand under a microscope. Blasts, Auer rods, and other clues can point to AML. ASH Publications

6. Bone marrow aspiration. A needle draws liquid marrow (often from the hip). The sample shows how many blasts are present and is used for flow cytometry and genetics. NCCN

7. Bone marrow core biopsy. A small core of bone is taken to assess cellularity, fibrosis, and architecture. It helps confirm AML and any background MDS changes. NCCN

8. Cytochemical stains (e.g., myeloperoxidase, Sudan Black B, nonspecific esterase). These special stains on smears help prove myeloid lineage when needed. ASH Publications

C) Laboratory and pathological tests (machines + molecular)

9. Complete blood count (CBC) with differential. Measures red cells, white cells, and platelets; often shows anemia, thrombocytopenia, and circulating blasts. Cancer.gov

10. Comprehensive metabolic panel and tumor lysis labs. Checks kidney and liver function, uric acid, potassium, phosphate, and LDH to spot complications. ASH Publications

11. Coagulation tests (PT/INR, aPTT, fibrinogen, D-dimer). These detect bleeding risk or DIC, which is common in APL and sometimes in other AML types. ASH Publications

12. Flow cytometry (immunophenotyping). Uses antibodies to define cell markers (e.g., CD13, CD33, MPO, CD34, HLA-DR) and confirms AML lineage and subtype. NCCN

13. Conventional cytogenetics (karyotype). Looks at whole chromosomes to find changes like t(8;21), inv(16), or complex karyotype. These changes define AML types and risk. ASH Publications

14. FISH (fluorescence in situ hybridization). A faster way to find specific chromosome changes when karyotype is unclear or urgent answers are needed. ASH Publications

15. Molecular testing (PCR/NGS). Detects gene mutations such as NPM1, FLT3-ITD/TKD, CEBPA, RUNX1, IDH1/2, TP53, KIT, ASXL1 and many others. These results anchor the modern diagnosis. ASH Publications

16. HLA typing (when a transplant might be considered). Identifies immune matches among family or unrelated donors early in the work-up. ASH Publications

D) Electrodiagnostic / monitoring tests (to assess complications and fitness)

17. Electrocardiogram (ECG). Anemia, infection, and high-output states strain the heart. ECG checks rhythm and detects ischemia or electrolyte-related changes. It also provides a baseline before certain drugs. ASH Publications

18. Pulse oximetry and basic cardiopulmonary monitoring. Quick, noninvasive checks for low oxygen from anemia, infection, or lung issues; guide urgent care decisions. ASH Publications

E) Imaging tests (to look for infection, masses, or organ effects)

19. Chest X-ray or chest CT. Looks for pneumonia, fungal disease, or fluid around the lungs when people have fever or cough. Cancer.gov

20. CT/MRI or PET-CT targeted to symptoms. Used when doctors suspect a myeloid sarcoma (chloroma) or spread to the brain, spine, or other sites; also used to define complications. Cancer.gov

Non-Pharmacological Treatments

A) Physiotherapy Interventions

1. Energy-conservation training
   Description: Teach pacing, task-splitting, and planned rest.
   Purpose: Reduce fatigue during treatment.
   Mechanism: Lowers total daily energy demand and prevents “boom-and-bust.”
   Benefits: More steady energy, fewer crashes, better daily function.

2. Graded activity program
   Description: Very gentle, stepwise activity plan tailored to blood counts.
   Purpose: Maintain strength without overexertion.
   Mechanism: Slow overload improves mitochondrial efficiency and conditioning.
   Benefits: Less deconditioning, better stamina, improved mood.

3. Low-impact aerobic walking
   Description: Short indoor walks or treadmill, with nurse/physio approval.
   Purpose: Support heart-lung fitness and circulation.
   Mechanism: Increases stroke volume and oxygen delivery safely.
   Benefits: Less dyspnea, lower resting heart rate, improved sleep.

4. Light resistance training
   Description: Bands or 1–2 kg weights for major muscle groups.
   Purpose: Preserve muscle mass during chemotherapy.
   Mechanism: Stimulates muscle protein synthesis despite catabolic stress.
   Benefits: Stronger grip, better transfers, improved independence.

5. Balance and fall-prevention drills
   Description: Static stance, tandem walk, sit-to-stand practice.
   Purpose: Cut fall risk when weak or dizzy.
   Mechanism: Trains proprioception and postural reflexes.
   Benefits: Fewer falls, more confidence, safer mobility.

6. Range-of-motion (ROM) stretching
   Description: Gentle daily stretches of neck, shoulders, hips, ankles.
   Purpose: Prevent stiffness from bed rest.
   Mechanism: Maintains tendon and joint capsule length.
   Benefits: Easier dressing, less pain, smoother movement.

7. Breathing exercises and incentive spirometry
   Description: Diaphragmatic breathing and device-guided deep breaths.
   Purpose: Prevent atelectasis and pneumonia.
   Mechanism: Re-expands alveoli and improves airway clearance.
   Benefits: Better oxygenation, fewer pulmonary complications.

8. Airway clearance & cough technique
   Description: Huff coughing and splinted cough with pillow support.
   Purpose: Clear secretions safely during neutropenia.
   Mechanism: Keeps small airways open and moves mucus proximally.
   Benefits: Less infection risk, easier breathing.

9. Neuropathy-friendly foot and hand therapy
   Description: Sensory re-education, gentle massage, protective footwear tips.
   Purpose: Ease chemotherapy-induced peripheral neuropathy.
   Mechanism: Enhances nerve signaling and protects insensate skin.
   Benefits: Less numbness/tingling distress, safer walking.

10. Orthostatic intolerance management
    Description: Slow position changes, ankle pumps, compression as allowed.
    Purpose: Reduce dizziness on standing.
    Mechanism: Improves venous return and autonomic adaptation.
    Benefits: Fewer near-falls, more confidence.

11. Posture and spine alignment coaching
    Description: Seated posture, ergonomic pillows, micro-breaks.
    Purpose: Decrease back/neck ache from prolonged bed rest.
    Mechanism: Reduces paraspinal strain and disc pressure.
    Benefits: Less pain, better comfort for reading and meals.

12. Gentle yoga or tai-chi (modified)
    Description: Chair-based flows cleared by the team.
    Purpose: Improve flexibility and calm.
    Mechanism: Combines ROM, balance, and mindful breathing.
    Benefits: Lower stress, better sleep, steady mobility.

13. Pelvic-floor and core activation
    Description: Simple core bracing and diaphragmatic-pelvic coordination.
    Purpose: Support cough, bowel, and back comfort.
    Mechanism: Improves intra-abdominal pressure control.
    Benefits: Less strain, better continence and transfers.

14. Edema control & limb elevation
    Description: Elevation timing, ankle pumps, gentle wraps if approved.
    Purpose: Reduce dependent swelling.
    Mechanism: Enhances lymphatic and venous return.
    Benefits: Less heaviness, improved shoe fit, comfort.

15. Sleep hygiene coaching
    Description: Dark/quiet routine, stimulus control, nap timing.
    Purpose: Restore restorative sleep despite hospital routines.
    Mechanism: Resets circadian cues and reduces arousal.
    Benefits: Better energy, mood, pain tolerance.

B) Mind-Body & Gene-Informed Lifestyle Supports

16. Guided relaxation and brief mindfulness
    Description: 10-minute breath scans or audio guidance twice daily.
    Purpose: Reduce stress, nausea perception, and pain.
    Mechanism: Lowers sympathetic tone and stress hormones.
    Benefits: Calmer mood, better treatment tolerance.

17. Cognitive-behavioral coping skills
    Description: Identify worries, reframe thoughts, plan actions.
    Purpose: Improve adherence and resilience.
    Mechanism: Alters appraisal of symptoms; strengthens problem-solving.
    Benefits: Less anxiety, clearer decisions.

18. Personalized activity on low-count days
    Description: Match steps and effort to absolute neutrophil/platelet counts.
    Purpose: Stay safe while moving.
    Mechanism: Risk-stratified prescriptions avoid bleeding and infection triggers.
    Benefits: Safety plus steady progress.

19. Anti-infection home routines
    Description: Hand hygiene, food safety, mask use in crowds.
    Purpose: Cut infection risk during neutropenia.
    Mechanism: Reduces pathogen exposure dose.
    Benefits: Fewer fevers and hospitalizations.

20. Genetics-aware counseling
    Description: Explain what FLT3, NPM1, IDH1/2, TP53 mean for care.
    Purpose: Improve understanding and consent.
    Mechanism: Links mutations to targeted options and prognosis.
    Benefits: Informed choices, realistic expectations.

C) Educational & Supportive Therapies

21. Medication map and calendar
    Description: Simple schedule with pictures and timing.
    Purpose: Prevent missed or double doses.
    Mechanism: External memory aid reduces cognitive load.
    Benefits: Safer treatment at home.

22. Nutrition counseling for neutropenia
    Description: Safe-food list, protein targets, hydration plan.
    Purpose: Maintain weight and healing.
    Mechanism: Adequate protein/energy supports marrow recovery.
    Benefits: Better strength, fewer GI upsets.

23. Oral-care training
    Description: Soft brush, alcohol-free rinses, lip balm routine.
    Purpose: Prevent mouth sores and infections.
    Mechanism: Protects mucosa and reduces bacterial load.
    Benefits: Easier eating, less pain.

24. Caregiver training and respite plan
    Description: Teach vitals, red flags, safe lifting, break scheduling.
    Purpose: Support home safety and reduce burnout.
    Mechanism: Skill-building and workload sharing.
    Benefits: Fewer errors, steadier support.

25. Return-to-work/school planning
    Description: Gradual duties, flexible timing, infection precautions.
    Purpose: Smooth reintegration.
    Mechanism: Stepwise exposure and energy budgeting.
    Benefits: Safer, more sustainable return.

---

Drug Treatments

Doses are typical adult ranges and must be individualized by an oncology team.

1. Cytarabine (antimetabolite)
   Dose/Time: 100–200 mg/m²/day continuous infusion for 7 days (induction “7+3”); or high-dose 1.5–3 g/m² q12h on days 1,3,5 (consolidation).
   Purpose: Core backbone to kill blasts.
   Mechanism: Ara-CTP inhibits DNA polymerase.
   Key side effects: Myelosuppression, mucositis, conjunctivitis, neurotoxicity at high dose.

2. Daunorubicin (anthracycline)
   Dose/Time: 60–90 mg/m² IV days 1–3 (with cytarabine).
   Purpose: Induction partner to deepen remission.
   Mechanism: DNA intercalation, topoisomerase-II inhibition.
   Side effects: Myelosuppression, cardiotoxicity, mucositis, alopecia.

3. Idarubicin (anthracycline)
   Dose/Time: 12 mg/m² IV days 1–3 as 7+3 variant.
   Purpose: Alternative to daunorubicin.
   Mechanism: Similar to daunorubicin with higher lipophilicity.
   Side effects: Myelosuppression, cardiomyopathy risk, nausea.

4. CPX-351 (liposomal daunorubicin/cytarabine)
   Dose/Time: 44/100 mg/m² IV on days 1, 3, 5 (induction) for secondary/therapy-related AML.
   Purpose: Improve outcomes in high-risk subtypes.
   Mechanism: Fixed 1:5 molar ratio, marrow-targeted liposomes.
   Side effects: Prolonged cytopenias, infections, nausea.

5. Gemtuzumab ozogamicin (anti-CD33 antibody-drug conjugate)
   Dose/Time: Commonly 3 mg/m² added to induction/consolidation in CD33+ AML.
   Purpose: Target CD33-positive blasts.
   Mechanism: Delivers calicheamicin toxin into CD33 cells.
   Side effects: Myelosuppression, liver injury/VOD risk, infusion reactions.

6. Midostaurin (FLT3 inhibitor)
   Dose/Time: 50 mg orally twice daily on days 8–21 with 7+3; then in consolidation.
   Purpose: For FLT3-mutated AML.
   Mechanism: Inhibits FLT3 signaling and proliferation.
   Side effects: Nausea, cytopenias, QT prolongation (monitor).

7. Gilteritinib (FLT3 inhibitor)
   Dose/Time: 120 mg orally once daily for relapsed/refractory FLT3-mutated AML.
   Purpose: Targeted monotherapy in relapse.
   Mechanism: Potent FLT3-ITD/TKD blockade.
   Side effects: Cytopenias, LFT elevation, differentiation syndrome.

8. Quizartinib (FLT3-ITD inhibitor)
   Dose/Time: Often 60 mg orally once daily in regimens approved for FLT3-ITD with chemo (per protocol).
   Purpose: Another FLT3-directed option.
   Mechanism: Selective FLT3-ITD inhibition.
   Side effects: QT prolongation, cytopenias; ECG monitoring.

9. Ivosidenib (IDH1 inhibitor)
   Dose/Time: 500 mg orally once daily.
   Purpose: For IDH1-mutated AML in various settings.
   Mechanism: Blocks mutant IDH1, lowers 2-HG, restores differentiation.
   Side effects: Differentiation syndrome, leukocytosis, QT prolongation.

10. Enasidenib (IDH2 inhibitor)
    Dose/Time: 100 mg orally once daily.
    Purpose: For IDH2-mutated AML.
    Mechanism: Blocks mutant IDH2 and reduces 2-HG.
    Side effects: Differentiation syndrome, hyperbilirubinemia, nausea.

11. Azacitidine (hypomethylating agent, SC/IV)
    Dose/Time: 75 mg/m² days 1–7 of 28-day cycles; often with venetoclax in unfit patients.
    Purpose: Lower-intensity therapy to induce remission.
    Mechanism: DNA hypomethylation reactivates tumor suppressor genes.
    Side effects: Cytopenias, injection reactions, GI upset.

12. Decitabine (hypomethylating agent, IV)
    Dose/Time: 20 mg/m² days 1–5 of 28-day cycles; may combine with venetoclax.
    Purpose: Alternative to azacitidine.
    Mechanism: Similar hypomethylation effect.
    Side effects: Cytopenias, infections, fatigue.

13. Venetoclax (BCL-2 inhibitor)
    Dose/Time: Ramp up to 400 mg daily; combined with azacitidine/decitabine or low-dose cytarabine.
    Purpose: Deepens remission in older/unfit or relapse settings.
    Mechanism: Triggers apoptosis by blocking BCL-2.
    Side effects: Tumor lysis, cytopenias, infections; careful dose with azoles.

14. All-trans retinoic acid—ATRA (differentiation agent)
    Dose/Time: ~45 mg/m²/day in divided doses; for acute promyelocytic leukemia (APL).
    Purpose: Induce differentiation and rapid coagulopathy control.
    Mechanism: Restores retinoic-acid receptor signaling.
    Side effects: Differentiation syndrome, headache, skin dryness.

15. Arsenic trioxide—ATO (differentiation agent)
    Dose/Time: 0.15 mg/kg/day IV per APL protocols.
    Purpose: Partner with ATRA in APL.
    Mechanism: Degrades PML-RARα fusion protein.
    Side effects: QT prolongation, electrolyte loss, liver enzyme rise.

Important: Doses, schedules, and combinations vary by age, kidney/liver function, genetic mutations, and local protocols. Your oncology team personalizes all decisions.

---

Dietary Molecular & Supportive Supplements

(Always clear with your oncology team; avoid during severe neutropenia unless approved; evidence strength varies.)

1. Vitamin D3: Typical 1,000–2,000 IU/day, titrate to 25(OH)D 30–50 ng/mL. Supports immune regulation and bone health; may improve muscle strength and mood. Mechanism: nuclear receptor effects on innate/adaptive immunity.

2. Omega-3 (EPA+DHA): 1–2 g/day. May help inflammation, appetite, and triglycerides. Mechanism: eicosanoid shift toward pro-resolving mediators. Watch bleeding risk if platelets low or on anticoagulants.

3. Oral glutamine: 10–30 g/day divided; may reduce mucositis and support gut lining in some regimens. Mechanism: fuel for enterocytes and immune cells. Discuss if renal issues.

4. High-protein whey or plant blend: 20–30 g once or twice daily to hit 1.2–1.5 g/kg/day protein. Mechanism: leucine-stimulated muscle protein synthesis. Helps maintain lean mass.

5. Psyllium soluble fiber: 5–10 g/day with fluids when not neutropenic with GI compromise. Mechanism: improves stool form and microbiome metabolites. Avoid if bowel obstruction risk.

6. Zinc (if deficient): 10–15 mg/day short term. Mechanism: enzymatic cofactor for immunity and taste. Excess can lower copper; monitor.

7. Folate (if deficient): 400 mcg/day dietary or supplement. Supports red cell production; avoid high doses without need while on antimetabolites—coordinate with team.

8. Vitamin B12 (if deficient): 1,000 mcg/day oral or periodic injections per labs. Supports neurologic function and hematopoiesis.

9. Magnesium (if low): 200–400 mg/day, form as tolerated. Helps cramps and arrhythmia risk, especially with drugs that lower Mg.

10. Selenium (if deficient): 100–200 mcg/day short term. Antioxidant selenoproteins support immune function; avoid excess.

---

Immunity-Support / Regenerative / Stem-Cell–Related” Drugs

(These are supportive or mobilizing—not anti-leukemia chemo. Use only when your team recommends.)

1. Filgrastim (G-CSF)
   Dose: ~5 mcg/kg/day SC until neutrophil recovery. Function: speeds neutrophil growth post-chemo. Mechanism: G-CSF receptor stimulation. Note bone pain; rare spleen issues.

2. Pegfilgrastim (long-acting G-CSF)
   Dose: 6 mg SC once per cycle when appropriate. Function: same as above with single injection. Mechanism: PEGylation prolongs half-life.

3. Sargramostim (GM-CSF)
   Dose: ~250 mcg/m²/day SC/IV. Function: stimulates neutrophils, monocytes. Mechanism: GM-CSF receptor activation. Can cause fever, bone pain.

4. Intravenous immunoglobulin (IVIG)
   Dose: e.g., 0.4 g/kg/day for 3–5 days in selected immune complications. Function: passive antibodies for hypogammaglobulinemia or infections. Mechanism: Fc-mediated immune modulation.

5. Plerixafor (CXCR4 antagonist)
   Dose: 0.24 mg/kg SC for stem-cell mobilization with G-CSF in transplant planning. Function: releases stem cells to blood for collection. Mechanism: blocks SDF-1/CXCR4 retention.

6. Eltrombopag or Romiplostim (TPO-R agonists, selected cases)
   Dose: Per protocol. Function: stimulate platelet production in refractory thrombocytopenia (not routine during curative AML induction). Mechanism: MPL receptor activation. Monitor for marrow fibrosis or interactions.

---

Procedures / “Surgeries”

1. Central venous catheter/port placement
   Procedure: Small operation to insert long-term IV access. Why: Reliable chemo, blood draws, transfusions.

2. Leukapheresis
   Procedure: Machine removes white cells from blood. Why: Short-term control of very high WBC to reduce leukostasis risk.

3. Lumbar puncture ± intrathecal chemo
   Procedure: Needle into lower back to sample CSF and deliver drugs. Why: Check/treat CNS involvement when indicated.

4. Hematopoietic stem cell transplantation (HSCT)
   Procedure: High-dose conditioning then donor or self stem-cell infusion. Why: Reduce relapse risk in intermediate/high-risk AML.

5. Splenectomy (rare, selected)
   Procedure: Surgical removal of spleen. Why: Severe hypersplenism causing refractory cytopenias or pain; uncommon in AML.

---

Preventions (Practical, Everyday)

1. Hand hygiene before meals and after bathroom.

2. Avoid raw/undercooked meats, eggs, unpasteurized foods.

3. Mask in crowded indoor spaces during neutropenia.

4. Daily oral care with soft brush and bland rinses.

5. Protect skin: moisturize; treat cuts promptly.

6. Avoid high-injury sports when platelets are low.

7. Keep vaccine schedule up-to-date for household contacts; you will follow oncologist guidance for yourself.

8. Review all supplements and medicines for interactions.

9. Adequate sleep and gentle activity most days.

10. Keep a symptom diary: fever, bruising, breathlessness, mouth sores.

---

When to See Doctors Urgently

• Fever ≥ 38.0 °C (100.4 °F) once, or chills/rigors.

• New bleeding, black stools, or many new bruises.

• Shortness of breath, chest pain, severe headache, confusion, fainting.

• Painful mouth sores with trouble eating or drinking.

• Red, hot, or draining skin around catheter.

• Sudden vision changes, stroke-like symptoms.

• Any fast change that worries you—call the team the same day.

---

Diet: What to Eat / What to Avoid

Eat more of:

1. Soft, high-protein foods: eggs (well-cooked), yogurt, tofu, fish fully cooked.

2. Beans and lentils well-cooked; add olive oil for calories.

3. Peeled, well-washed fruits; cooked vegetables and soups.

4. Whole grains if tolerated: oatmeal, rice, pasta.

5. Fluids: water, oral rehydration, broths.

Limit/avoid:

1. Raw sushi, runny eggs, unpasteurized milk/cheese.
2. Raw sprouts; salad bars during neutropenia.
3. Alcohol and energy drinks; they worsen dehydration.
4. Grapefruit/Seville orange with certain chemo/targeted drugs (CYP3A4 interactions—ask your team).
5. Herbal megadoses that interact with chemo (e.g., St. John’s wort, high-dose green tea extracts) unless approved.

---

Frequently Asked Questions

1. Is AML the same as APL?
   APL is a special subtype of AML with the PML-RARα fusion. It uses ATRA and arsenic and needs urgent care for bleeding risk.

2. Can AML be cured?
   Yes. Cure rates depend on age, fitness, and genetics. Many people enter long-term remission, especially with mutation-matched therapy and, when needed, transplant.

3. Why are genetics so important?
   Mutations like FLT3, NPM1, IDH1/2, and TP53 guide which drugs work best and how likely relapse is. Your care is personalized to these results.

4. What is “7+3”?
   Seven days of cytarabine plus 3 days of an anthracycline (daunorubicin/idarubicin). It’s a standard induction to clear blasts.

5. What is minimal/measurable residual disease (MRD)?
   Very small amounts of leukemia left after treatment. Sensitive tests detect it. MRD guides next steps and relapse risk.

6. Will I need a transplant?
   Some people do—often those with intermediate or high-risk genetics or persistent MRD. Your team weighs risks and benefits.

7. How long does treatment last?
   Induction is weeks; consolidation or maintenance may last months to a couple of years, with clinic monitoring.

8. Why are transfusions common?
   Chemo lowers red cells and platelets. Transfusions treat symptoms and prevent bleeding while marrow recovers.

9. How do I handle nausea and appetite loss?
   Tell your team early. Anti-nausea drugs, small frequent meals, high-protein shakes, and mouth care help.

10. Can I exercise during treatment?
    Yes—gentle, supervised activity is encouraged when counts and symptoms allow. It improves strength and mood.

11. Are infections inevitable?
    Risk is high, but careful hygiene, prompt fever reporting, and sometimes preventive antibiotics/antifungals reduce danger.

12. What is differentiation syndrome?
    A rapid inflammatory reaction seen with ATRA/IDH inhibitors. Symptoms include fever, fluid in lungs, low blood pressure. It needs urgent steroids—report symptoms fast.

13. What about fertility?
    Chemo can affect fertility. Ask early about sperm/egg preservation before treatment when possible.

14. Can I take vitamins or herbs?
    Only with team approval. Some interact with chemo or targeted drugs. Blood tests will show if you truly need supplements.

15. How will follow-up work after remission?
    Regular visits with blood tests, sometimes bone-marrow checks, and MRD monitoring. Report new symptoms quickly.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 07, 2025.